ORIGINAL RESEARCH
Published on 03 Oct 2025
Efficacy and safety of the third-generation tyrosine kinase inhibitor Olverembatinib in relapsed and persistent minimal residual disease positive Philadelphia chromosome-positive acute lymphoblastic leukemia patients
doi 10.3389/fmed.2025.1662512
- 673 views